ライフサイエンスコーパス: neutron capture therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ) was synthesized for potential use in boron neutron capture therapy.

2 ntially could be used as delivery agents for neutron capture therapy.

3 boronated EGF to EGFR (+) gliomas for boron neutron capture therapy.

4 investigated as a potential agent for boron neutron capture therapy.

5 delivery and subsequent application in boron neutron capture therapy.

6 PA, and, subsequently, the efficacy of boron neutron capture therapy.

7 sting templates as carriers of 10B for boron neutron capture therapy.

8 , inhibition of hydrolytic enzymes and boron neutron capture therapy.

9 potential in traditional areas such as Boron Neutron Capture Therapy agents, but also as pharmacophor

10 Protons, neutrons, pions, boron-neutron capture therapy, and charged-nuclei therapy (wit

11 cleotides are potential candidates for boron neutron capture therapy, antisense technology, and as to

12 ufficient amounts of 10B for effective boron neutron capture therapy ( approximately 10(8)-10(9) 10B

13 The application of boron neutron capture therapy (BNCT) following liposomal deliv

14 Success of boron neutron capture therapy (BNCT) is dependent on cellular

15 Boron neutron capture therapy (BNCT) is dependent on the selec

16 The application of boron neutron capture therapy (BNCT) mediated by liposomes con

17 -yl] thymidine, designated N5-2OH, for boron neutron capture therapy (BNCT) of brain tumors using the

18 Boron neutron capture therapy (BNCT) using 4-[10B]boronophenyl

19 Boron neutron capture therapy (BNCT), a binary treatment modal

20 Boron neutron capture therapy (BNCT), an experimental treatmen

21 as potential boron delivery agents for boron neutron capture therapy (BNCT).

22 e 2 was also tested as a candidate for boron neutron capture therapy, but showed poor tumor retention

23 exceptional challenge, because viable boron neutron-capture therapy by this method will require the

24 s to determine whether the efficacy of boron neutron capture therapy could be enhanced by means of in

25 The viability of boron neutron capture therapy depends on the development of tu

26 These studies with boron neutron capture therapy for CIA suggest that this form o

27 ylalanine has been applied in clinical boron neutron capture therapy for the treatment of high-grade

28 linked to epidermal growth factor (EGF) for neutron capture therapy in rats bearing a syngeneic epid

29 sign and synthesis of therapeutics for boron neutron capture therapy of cancer.

30 two clinically approved drugs used in boron neutron capture therapy of cancer.

31 gest that this agent may be useful for boron neutron capture therapy of cancer.

32 aining compounds that maybe useful for boron neutron capture therapy of tumors.

33 tein-based targeting strategies to the boron neutron-capture therapy of cancer poses an exceptional c

34 n these favorable in vitro and in vivo data, neutron capture therapy studies will be initiated using

35 The application of boron neutron capture therapy to rheumatoid arthritis requires

36 on cluster system, previously used for boron neutron capture therapy, was modified by the addition of

37 boronated EGF as a delivery agent for boron neutron capture therapy, which is based on the capture r

38 o a novel class of boron delivery agents for neutron capture therapy, which was designated 3-carboran

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。